Excessive Pricing Cases in the Pharmaceutical Sector

This document is a report detailing the recent proliferation of excessive pricing cases in the pharmaceutical sector, particularly in the post-pandemic period from 2021 to 2023. It outlines the historical rarity of such cases due to antitrust agencies' reluctance to engage in price regulation, with a focus on off-patent and orphan drugs. The report presents specific cases from various countries, including the European Union, the UK, China, and Israel, highlighting significant price increases and the outcomes of regulatory actions. For instance, it discusses Aspen's price hikes of off-patent cancer medicines and the subsequent commitments made to supply at reduced prices. The document also emphasizes the enforcement priorities of regulatory bodies, noting that substantial price increases must be justified and documented. Additionally, it provides practical takeaways for stakeholders in the pharmaceutical industry regarding pricing strategies and regulatory scrutiny.